Back to Search
DANIEL ROSSIGNOL, MD
MD
Family Medicine Physician
NPI: 1821076431Individual
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
0101058228(VA)ME97209(FL)C54759(CA)
Research & Publications (20)
Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial.
PMID 19284641·BMC Pediatr·2009
4-observational
The effects of hyperbaric oxygen therapy on oxidative stress, inflammation, and symptoms in children with autism: an open-label pilot study.
PMID 18005455·BMC Pediatr·2007
8-other
Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers.
PMID 19039062·Innate Immun·2008
8-other
Influence of plasma cholesterol and triglyceride concentrations and eritoran (E5564) micelle size on its plasma pharmacokinetics and ex vivo activity following single intravenous bolus dose into healthy female rabbits.
PMID 17849177·Pharm Res·2008
7-preclinical
A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass.
PMID 17242095·Anesth Analg·2007
3-trial
Spironolactone might be a desirable immunologic and hormonal intervention in autism spectrum disorders.
PMID 17150311·Med Hypotheses·2007
8-other
Hyperbaric oxygen therapy might improve certain pathophysiological findings in autism.
PMID 17141962·Med Hypotheses·2007
8-other
Elevated plasma levels of limulus amoebocyte lysate-reactive material.
PMID 17041863·J Infect Dis·2006
7-preclinical
Effects of decreased preoperative endotoxin core antibody levels on long-term mortality after coronary artery bypass graft surgery.
PMID 16847232·Arch Surg·2006
4-observational
Hyperbaric oxygen therapy may improve symptoms in autistic children.
PMID 16554123·Med Hypotheses·2006
5-case
Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers.
PMID 15328078·Antimicrob Agents Chemother·2004
8-other
Inhibition of endotoxin response by synthetic TLR4 antagonists.
PMID 15279606·Curr Top Med Chem·2004
6-review
Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected].
PMID 14566003·J Pharmacol Exp Ther·2004
3-trial
Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrations.
PMID 12936976·Antimicrob Agents Chemother·2003
7-preclinical
Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study.
PMID 12856387·J Clin Pharmacol·2003
3-trial
Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist.
PMID 12604686·J Pharmacol Exp Ther·2003
7-preclinical
Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia.
PMID 12599080·J Infect Dis·2003
3-trial
Lower endotoxin immunity predicts increased cognitive dysfunction in elderly patients after cardiac surgery.
PMID 12574568·Stroke·2003
8-other
Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue.
PMID 12697095·J Endotoxin Res·2002
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 24541 PACIFIC PARK DR STE 210
ALISO VIEJO, CA 92656 - Phone
- (321) 259-7111
Quick Facts
- NPI
- 1821076431
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 3
- Locations
- 2
- Publications
- 20
Are you this provider?
Claim Your Profile